ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020
PET Imaging of the Natural Killer Cell Activation Receptor NKp30.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma.Frontiers in immunology · 2025Review
- Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective.Molecular cancer · 2024Review
- ImmunoPET provides a novel way to visualize the CD103EJNMMI research · 2024Review
- Review
- Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment.Molecular imaging and biology · 2023Review
- Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.Scientific reports · 2023Article
- Review
- Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.Biomedicines · 2022Review
- MRI and PET of Brain Tumor Neuroinflammation in the Era of Immunotherapy, From theAJR. American journal of roentgenology · 2022Review
- Probing immune infiltration dynamics in cancer by in vivo imaging.Current opinion in chemical biology · 2022Review
- In Vivo Cell Tracking Using PET: Opportunities and Challenges for Clinical Translation in Oncology.Cancers · 2021Review
- TheFrontiers in oncology · 2021Article
- Noninvasive Imaging of Cancer Immunotherapy.Nanotheranostics · 2021Review
- NKp30 - A prospective target for new cancer immunotherapy strategies.British journal of pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Redirecting the immune system in cancer treatment has led to remarkable responses in a subset of patients. Natural killer (NK) cells are innate lymphoid cells being explored as they engage tumor cells in different mechanisms compared with T cells, which could be exploited for treatment of nonresponders to current immunotherapies. NK cell therapies are monitored through measuring peripheral NK cell concentrations or changes in tumor volume over time. The former does not detect NK cells at the tumor site, and the latter is inaccurate for immunotherapies because of pseudoprogression. Therefore, new imaging methods are required as companion diagnostics for optimizing immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.